Nucleate SG Annual Biomixer 2026
Celebrating 3 wonderful years, Nucleate Singapore (founded Aug 2023) is back again with our annual Biomixer, a networking social event for the Life Sciences community.
This event aims to bring together partners and individuals for an evening of celebrating Nucleate Singapore's achievements, fostering connections, and sparking collaborations within academia & industry.
Nucleate Singapore will be spending 10-15 minutes to describe Nucleate and its early days, the Singapore Chapter's year in review and plans for the upcoming year. After that, we will commence the panel discussion surrounding this year's theme of "Future Trends of Biotech In Singapore", with our highly esteemed panelists.
The night will then end with casual interactions over food and drinks. Through organic casual conversations, the aim is to establish these events as a networking platform for biotech enthusiasts in industry & academia.
Dr. Olivia (Yue) Geng is a life sciences executive with more than 15 years of leadership experience spanning drug discovery, advanced research platforms, biotechnology commercialization, and strategic growth across North America and Asia-Pacific. She currently serves as Executive Director, Strategic Partnerships & Innovation at Altea Investments, a Hillhouse Investment-backed life sciences platform developing and investing in research and innovation infrastructure across Asia-Pacific. In this role, she leads strategic partnerships with leading universities, research institutes, biotechnology companies, pharmaceutical organizations, investors, and government agencies to accelerate scientific innovation and strengthen cross-border life sciences ecosystems.
Prior to Altea, Dr. Geng spent nearly seven years at Berkeley Lights (now Bruker Cellular Analysis), where she held several executive leadership roles. Her expertise includes commercialization of emerging technologies, Asia-Pacific market expansion, strategic partnerships, cross-border business development, innovation ecosystem development, and corporate growth strategy.
Dr. Chen is an experienced life sciences operating executive and investment professional. In her role at ALSP, Alice has been actively involved in identifying and evaluating emerging biotechnology investment opportunities and has played an instrumental role in the formation, oversight, and transaction of several Accelerator portfolio companies, including Acylin Therapeutics (asset acquisition by a global pharmaceutical company), Petra Pharma (acquired by a global pharmaceutical company), Nemean Pharma, Rodeo Therapeutics(acquired by Amgen Inc.), Magnolia Neurosciences, and Automera. She has served in various operational leadership roles across portfolio companies and is currently on the Board of Directors for Automera.
Dr. Chen received a Ph.D. in Chemical Engineering from Stanford University and a B.S. degree in Chemical Engineering from U.C. Berkeley. She served as an Engineering Fellow at Merck & Company and is a graduate of the Kauffman Fellows Program (Class 19). Alice served on the board of Life Science Washington, the state’s life-science trade association, for six years prior to her current post as ALSP’s head of operations in Singapore. She is a current member of various technology review committees in the U.S. and abroad.
Robert Ang, MBBS, MBA, is currently CEO of a stealth biotech company in Singapore. He was previously President and CEO at Vor Bio, a biotech company working on next-generation stem cell transplants, gene editing, and CAR-T technologies toward treatments in blood cancers. Under his leadership, Vor raised over $100M privately, IPOed, and raised over $500M from public financing, pushing two first-in-class programs to human proof of concept.
Prior to Vor, Robert had operational experience focused on strategy and business development roles at Neon Therapeutics (now BioNTech), Bavarian Nordic, and Cadence Pharmaceuticals (now Mallinckrodt). Robert also had biotech venture capital experience at Frazier Healthcare Ventures and strategy experience at the Boston Consulting Group. He received his medical degree at the University of Western Australia and has an MBA with Honors from Columbia Business School. Robert also serves as Chair at Enara Bio, independent board member at Kolon TissueGene and the Experimental Drug Development Center at A*STAR, and serves on the Executive Committee and Board at the Alliance for Regenerative Medicine.
PLEASE NOTE:
By filling in this RSVP form, you are consenting to the use of photographs taken during the event (which may contain your picture) for publicity purposes.
You will be added to our mailing list, but you may unsubscribe through Substack any time you wish.
Your name, email address and affiliations may be shared with our sponsors for marketing purposes.
About the Host:
Nucleate is a 501(c)(3) nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 41 geographic regions and participation from over 280 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies. Visit www.nucleate.org for more information, and visit https://nucleate.org/privacy-policy/ to read our privacy policy.
We want to thank our HQ supporters for championing our open-access mission and empowering the next generation of biotech entrepreneurs!: